RCKT
NASDAQ · Biotechnology
Rocket Pharmaceuticals Inc
$3.37
-0.13 (-3.71%)
Open$3.47
Previous Close$3.50
Day High$3.56
Day Low$3.35
52W High$5.45
52W Low$2.53
Volume—
Avg Volume1.59M
Market Cap384.21M
P/E Ratio—
EPS$-0.18
SectorBiotechnology
Analyst Ratings
Buy
20 analysts
Price Target
+400.6% upside
Current
$3.37
$3.37
Target
$16.87
$16.87
$13.87
$16.87 avg
$23.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 67.67M | 66.73M | 71.52M |
| Net Income | -17,020,193 | -15,934,880 | -16,470,876 |
| Profit Margin | -25.2% | -23.9% | -23.0% |
| EBITDA | -23,292,743 | -22,716,839 | -22,207,941 |
| Free Cash Flow | -11,691,320 | -15,075,459 | -16,131,538 |
| Rev Growth | +1.5% | +16.6% | +10.7% |
| Debt/Equity | 1.36 | 1.21 | 1.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |